Morepen Unveils Empamore for Affordable Diabetes Treatment

Morepen Laboratories Limited has announced the introduction of Empamore, a revolutionary medication for Chronic Kidney Disease (CKD), Heart Failure with Reduced Ejection Fraction (HFrEF), and Type 2 Diabetes Mellitus (T2DM). Empamore is positioned to make a big difference by providing high-quality treatment at a reasonable cost, enabling millions of Indians to take charge of their health. India is the diabetes capital of the world, with over 101 million people living with the condition.

“At Morepen, we are dedicated to democratizing healthcare by making world-class treatments accessible to all. With Empamore, we are providing a trusted, high-quality diabetes treatment at nearly 90% lower cost than existing brands, helping millions manage their condition effectively without financial strain. This aligns with our commitment to empower people to take charge of their health.” Ashutosh Sharma, V.P. - Sales & Marketing, Morepen Laboratories, said.

Morepen already has a European DMF and produces empagliflozin (API) in facilities authorized by the USFDA. Morepen's 40 years of pharmaceutical excellence are reflected in the debut of Empamore, which offers a more affordable option to well-known brands without sacrificing quality.

One well-known SGLT2 inhibitor that is frequently used to treat diabetes is empagliflozin. Morepen's debut of Empamore comes at a critical moment to offer an economical and efficient solution, as the number of pre-diabetes cases in India is estimated to reach almost 136 million, and the diabetes market is projected to rise at a CAGR of 10.9%.